| Characteristic . | All patients (n = 65), n (%) . | Patients treated with anti‐PD1 (n = 19), n (%) . |
|---|---|---|
| Age at diagnosis, median (range), years | 65 (47–87) | 68 (50–84) |
| Race | ||
| Black | 9 (14) | 4 (21) |
| Asian | 2 (3) | 1 (5) |
| White | 45 (69) | 12 (63) |
| Unknown | 9 (14) | 2 (11) |
| PSA at diagnosis, median (range), ng/mL | 16 (1–5,786) | 31 (2.7–5,786) |
| Grade group at diagnosis | ||
| 2 | 5 (8) | 2 (10) |
| 3 | 10 (15) | 3 (16) |
| 4 | 6 (9) | 0 (0) |
| 5 | 35 (54) | 10 (53) |
| Result unavailable | 9 (14) | 4 (21) |
| Atypical histology at diagnosis | ||
| None | 54 (83) | 17 (89) |
| Ductal or intraductal | 6 (9) | 2 (11) |
| Cribriform features | 3 (5) | 0 (0) |
| Neuroendocrine/small cell | 2 (3) | 0 (0) |
| Presence of perineural invasion | 18 (28) | 6 (32) |
| Clinical stage at diagnosis | ||
| TxN0M0 | 34 (52) | 8 (42) |
| TxN1M0 | 8 (12) | 2 (11) |
| TxNxM1 | 23 (36) | 9 (47) |
| Low volume disease | 8 (35) | 4 (44) |
| High volume disease | 15 (65) | 5 (56) |
| Last known disease state, n | ||
| Nonmetastatic | 16 | 0 |
| Metastatic | 49 | 19 |
| Sites of metastases | ||
| Bone | 36 (73) | 15 (79) |
| Bone only | 17 (35) | 5 (26) |
| Lymph node | 25 (51) | 11 (58) |
| Visceral | 18 (37) | 7 (37) |
| Presence of secondary malignancy | 9 (14) | 2 |
| Family history of cancer: First‐degree relative | 39 (60) | 16 (84) |
| Characteristic . | All patients (n = 65), n (%) . | Patients treated with anti‐PD1 (n = 19), n (%) . |
|---|---|---|
| Age at diagnosis, median (range), years | 65 (47–87) | 68 (50–84) |
| Race | ||
| Black | 9 (14) | 4 (21) |
| Asian | 2 (3) | 1 (5) |
| White | 45 (69) | 12 (63) |
| Unknown | 9 (14) | 2 (11) |
| PSA at diagnosis, median (range), ng/mL | 16 (1–5,786) | 31 (2.7–5,786) |
| Grade group at diagnosis | ||
| 2 | 5 (8) | 2 (10) |
| 3 | 10 (15) | 3 (16) |
| 4 | 6 (9) | 0 (0) |
| 5 | 35 (54) | 10 (53) |
| Result unavailable | 9 (14) | 4 (21) |
| Atypical histology at diagnosis | ||
| None | 54 (83) | 17 (89) |
| Ductal or intraductal | 6 (9) | 2 (11) |
| Cribriform features | 3 (5) | 0 (0) |
| Neuroendocrine/small cell | 2 (3) | 0 (0) |
| Presence of perineural invasion | 18 (28) | 6 (32) |
| Clinical stage at diagnosis | ||
| TxN0M0 | 34 (52) | 8 (42) |
| TxN1M0 | 8 (12) | 2 (11) |
| TxNxM1 | 23 (36) | 9 (47) |
| Low volume disease | 8 (35) | 4 (44) |
| High volume disease | 15 (65) | 5 (56) |
| Last known disease state, n | ||
| Nonmetastatic | 16 | 0 |
| Metastatic | 49 | 19 |
| Sites of metastases | ||
| Bone | 36 (73) | 15 (79) |
| Bone only | 17 (35) | 5 (26) |
| Lymph node | 25 (51) | 11 (58) |
| Visceral | 18 (37) | 7 (37) |
| Presence of secondary malignancy | 9 (14) | 2 |
| Family history of cancer: First‐degree relative | 39 (60) | 16 (84) |
Abbreviation: PSA, prostate‐specific antigen.
| Characteristic . | All patients (n = 65), n (%) . | Patients treated with anti‐PD1 (n = 19), n (%) . |
|---|---|---|
| Age at diagnosis, median (range), years | 65 (47–87) | 68 (50–84) |
| Race | ||
| Black | 9 (14) | 4 (21) |
| Asian | 2 (3) | 1 (5) |
| White | 45 (69) | 12 (63) |
| Unknown | 9 (14) | 2 (11) |
| PSA at diagnosis, median (range), ng/mL | 16 (1–5,786) | 31 (2.7–5,786) |
| Grade group at diagnosis | ||
| 2 | 5 (8) | 2 (10) |
| 3 | 10 (15) | 3 (16) |
| 4 | 6 (9) | 0 (0) |
| 5 | 35 (54) | 10 (53) |
| Result unavailable | 9 (14) | 4 (21) |
| Atypical histology at diagnosis | ||
| None | 54 (83) | 17 (89) |
| Ductal or intraductal | 6 (9) | 2 (11) |
| Cribriform features | 3 (5) | 0 (0) |
| Neuroendocrine/small cell | 2 (3) | 0 (0) |
| Presence of perineural invasion | 18 (28) | 6 (32) |
| Clinical stage at diagnosis | ||
| TxN0M0 | 34 (52) | 8 (42) |
| TxN1M0 | 8 (12) | 2 (11) |
| TxNxM1 | 23 (36) | 9 (47) |
| Low volume disease | 8 (35) | 4 (44) |
| High volume disease | 15 (65) | 5 (56) |
| Last known disease state, n | ||
| Nonmetastatic | 16 | 0 |
| Metastatic | 49 | 19 |
| Sites of metastases | ||
| Bone | 36 (73) | 15 (79) |
| Bone only | 17 (35) | 5 (26) |
| Lymph node | 25 (51) | 11 (58) |
| Visceral | 18 (37) | 7 (37) |
| Presence of secondary malignancy | 9 (14) | 2 |
| Family history of cancer: First‐degree relative | 39 (60) | 16 (84) |
| Characteristic . | All patients (n = 65), n (%) . | Patients treated with anti‐PD1 (n = 19), n (%) . |
|---|---|---|
| Age at diagnosis, median (range), years | 65 (47–87) | 68 (50–84) |
| Race | ||
| Black | 9 (14) | 4 (21) |
| Asian | 2 (3) | 1 (5) |
| White | 45 (69) | 12 (63) |
| Unknown | 9 (14) | 2 (11) |
| PSA at diagnosis, median (range), ng/mL | 16 (1–5,786) | 31 (2.7–5,786) |
| Grade group at diagnosis | ||
| 2 | 5 (8) | 2 (10) |
| 3 | 10 (15) | 3 (16) |
| 4 | 6 (9) | 0 (0) |
| 5 | 35 (54) | 10 (53) |
| Result unavailable | 9 (14) | 4 (21) |
| Atypical histology at diagnosis | ||
| None | 54 (83) | 17 (89) |
| Ductal or intraductal | 6 (9) | 2 (11) |
| Cribriform features | 3 (5) | 0 (0) |
| Neuroendocrine/small cell | 2 (3) | 0 (0) |
| Presence of perineural invasion | 18 (28) | 6 (32) |
| Clinical stage at diagnosis | ||
| TxN0M0 | 34 (52) | 8 (42) |
| TxN1M0 | 8 (12) | 2 (11) |
| TxNxM1 | 23 (36) | 9 (47) |
| Low volume disease | 8 (35) | 4 (44) |
| High volume disease | 15 (65) | 5 (56) |
| Last known disease state, n | ||
| Nonmetastatic | 16 | 0 |
| Metastatic | 49 | 19 |
| Sites of metastases | ||
| Bone | 36 (73) | 15 (79) |
| Bone only | 17 (35) | 5 (26) |
| Lymph node | 25 (51) | 11 (58) |
| Visceral | 18 (37) | 7 (37) |
| Presence of secondary malignancy | 9 (14) | 2 |
| Family history of cancer: First‐degree relative | 39 (60) | 16 (84) |
Abbreviation: PSA, prostate‐specific antigen.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
